Want to see GB:HLN full AI Analyst Report?
Top Page
Haleon PLC
(LSE:HLN)
Select Model
Select Model
Rating:67Neutral
Price Target:
377.00 p
▲(5.13% Upside)
Action:Downgraded
Date:02/26/26
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
Positive Factors
Consistent free cash flow generation
Durable, high-quality cash generation (~1.7–2.0B FCF) provides recurring internal funding for A&P, R&D, debt reduction and capex. This persistent cash conversion supports strategic reinvestment and financial flexibility, cushioning the company through cycles and enabling execution of medium-term initiatives.
Negative Factors
Weak volume growth versus peers
Persistent low volume contribution (~1% average) suggests structural demand or execution gaps that limit organic top‑line expansion. Reliance on pricing or mix to hit growth targets risks sustainability; the company must materially lift unit growth to reliably deliver 4–6% medium‑term ambitions.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent free cash flow generation
Durable, high-quality cash generation (~1.7–2.0B FCF) provides recurring internal funding for A&P, R&D, debt reduction and capex. This persistent cash conversion supports strategic reinvestment and financial flexibility, cushioning the company through cycles and enabling execution of medium-term initiatives.
Read all positive factors
Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£31.74B
Dividend Yield1.51%
Average Volume (3M)23.77M
Price to Earnings (P/E)31.5
Beta (1Y)0.44
Revenue Growth-1.81%
EPS Growth17.54%
CountryUK
Employees24,561
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.16
Shares Outstanding8,808,899,000
10 Day Avg. Volume25,018,353
30 Day Avg. Volume23,772,072
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£410.00Price Target Upside14.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)0.21
Revenue Forecast (FY)£11.40B
Haleon PLC Business Overview & Revenue Model
Company Description
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin A...
How the Company Makes Money
Haleon makes money primarily by selling branded consumer healthcare products to retailers, wholesalers, pharmacies, and e-commerce customers. Revenue is generated from product sales across its major categories (e.g., oral health, pain relief, resp...
Haleon PLC Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presented a mixed picture: strong operational and margin progress (220 bps gross margin improvement), clear portfolio wins in Oral Health, meaningful cost-savings plans ($175–$200m) and strong emerging market execution (India, China). Offsetting this were persistent top-line and volume weaknesses, a weak cold & flu season (impacting the U.S. and other regions), channel inventory destocking and category-specific pressures (e.g., Nexium). Management signaled confidence in returning to medium-term growth targets but provided a conservative near-term organic guidance range (3%–5%) reflecting market uncertainty.Positive Updates
Organic Sales Growth Guidance
Guided organic sales growth of 3%–5% for FY2026, and reiterated medium-term ambition of 4%–6% despite FY2025 organic growth of 3%.
Negative Updates
U.S. Market Softness
U.S. sales were down approximately 0.5% in FY2025; company expects the U.S. cold and flu season to be below prior year in Q1 and recognized the U.S. remains a key area requiring improvement to hit medium-term targets.
Read all updates
Q4-2025 Updates
Positive
Negative
Organic Sales Growth Guidance
Guided organic sales growth of 3%–5% for FY2026, and reiterated medium-term ambition of 4%–6% despite FY2025 organic growth of 3%.
Read all positive updates
Company Guidance
Management guided 2026 organic sales growth of 3–5% (with a medium‑term ambition of 4–6%), noting FY25 organic growth was 3% (U.S. -0.5%) and that Q1 cold & flu is expected to be below a year ago but the U.S. should return to growth in 2026; they cited 220 basis points of gross‑margin improvement in 2025, $175–200m of gross savings from the reorganisation, and the ability to deliver high‑single‑digit operating growth at constant currency while still investing for growth, with 50–80 bps of supply‑chain productivity built into guidance; A&P rose ~7.5% (to ~20.5% of sales) and R&D +7.7%, working media was +12%, ROI improved mid‑single digits with ~75% coverage, and emerging markets showed strong metrics (India double‑digit growth, China e‑commerce ~40% of sales, Douyin >100% growth).Haleon PLC Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
63
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.02B | 11.03B | 11.23B | 11.30B | 10.86B | 9.54B |
| Gross Profit | 6.81B | 7.14B | 6.82B | 6.75B | 6.73B | 5.95B |
| EBITDA | 2.79B | 2.85B | 2.68B | 2.67B | 2.68B | 2.21B |
| Net Income | 1.52B | 1.67B | 1.44B | 1.05B | 1.06B | 1.39B |
Balance Sheet | ||||||
| Total Assets | 31.83B | 32.63B | 34.31B | 34.05B | 34.81B | 34.45B |
| Cash, Cash Equivalents and Short-Term Investments | 676.00M | 1.32B | 2.19B | 1.04B | 684.00M | 414.00M |
| Total Debt | 8.54B | 8.61B | 10.10B | 9.46B | 10.44B | 991.00M |
| Total Liabilities | 15.83B | 16.15B | 18.09B | 17.33B | 18.36B | 7.97B |
| Stockholders Equity | 15.94B | 16.43B | 16.17B | 16.61B | 16.33B | 26.36B |
Cash Flow | ||||||
| Free Cash Flow | 931.00M | 2.02B | 1.98B | 1.76B | 1.74B | 1.06B |
| Operating Cash Flow | 1.03B | 2.34B | 2.30B | 2.10B | 2.06B | 1.36B |
| Investing Cash Flow | -76.00M | -580.00M | 528.00M | -134.00M | -8.78B | -33.00M |
| Financing Cash Flow | -2.52B | -2.61B | -1.54B | -1.57B | 6.91B | -1.24B |
Haleon PLC Technical Analysis
Positive
358.60
Price Trends
339.15
Positive
357.43
Positive
356.74
Positive
Market Momentum
5.15
Negative
72.68
Negative
90.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HLN, the sentiment is Positive. The current price of 358.6 is above the 20-day moving average (MA) of 341.36, above the 50-day MA of 339.15, and above the 200-day MA of 356.74, indicating a bullish trend. The MACD of 5.15 indicates Negative momentum. The RSI at 72.68 is Negative, neither overbought nor oversold. The STOCH value of 90.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:HLN.
Haleon PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £31.74B | 31.48 | 6.43% | 1.51% | -1.81% | 17.54% | |
60 Neutral | £80.07M | 15.14 | 7.82% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £30.26M | -50.12 | -49.45% | ― | -27.38% | -50.00% | |
41 Neutral | £417.95M | -6.53 | 409.00% | ― | 2.94% | -32.00% | |
41 Neutral | £64.71M | -4.64 | 121.87% | ― | 49.81% | 52.94% |
* Healthcare Sector Average
GB:HLN
Haleon PLC
364.30
0.18
0.05%
GB:AGY
Allergy Therapeutics
6.60
-1.40
-17.50%
GB:PXS
Provexis
1.26
0.41
48.24%
GB:STX
Shield Therapeutics
6.15
3.30
115.79%
GB:VLG
Venture Life
66.50
7.50
12.71%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
45.00
7.50
20.00%
Haleon PLC Corporate Events
Regulatory Filings and Compliance
Haleon updates market on total voting rights and share capital
Neutral
Jul 1, 2026
Haleon plc has reported that as of 30 June 2026 it has issued 8,820,906,422 ordinary shares, of which 12,006,714 are held in treasury, leaving 8,808,899,708 shares carrying voting rights. The company noted that this voting share figure should be u...
Stock BuybackRegulatory Filings and Compliance
Haleon Cancels Nearly 7 Million Shares in Ongoing Buyback Programme
Positive
Jun 29, 2026
Haleon has repurchased 6,992,435 ordinary shares for cancellation as part of its ongoing share buyback programme launched in March 2026. The purchases, executed across the London Stock Exchange and multiple alternative trading venues on 22 and 23 ...
Stock BuybackRegulatory Filings and Compliance
Haleon Cancels 14.3 Million Shares Under Ongoing Buyback Programme
Positive
Jun 22, 2026
Haleon PLC has cancelled 14,288,204 ordinary shares as part of its ongoing share buyback programme, executed through purchases on multiple UK trading venues between 16 and 18 June 2026. Following these transactions, the company’s registered ...
Business Operations and StrategyStock Buyback
Haleon cancels 565,285 shares under ongoing buyback programme
Positive
Jun 15, 2026
Haleon PLC has repurchased 565,285 ordinary shares for cancellation as part of its share buyback programme announced in March 2026, paying a volume‑weighted average price of 331.9552 pence per share on 8 June 2026. The move forms part of the...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon Cancels 16.6 Million Shares in Ongoing Buyback Programme
Positive
Jun 8, 2026
Haleon plc has cancelled 16,585,448 ordinary shares as part of its ongoing share buyback programme, with purchases executed across the London Stock Exchange, Cboe UK venues and Aquis between 1 and 4 June 2026. Following these transactions, Haleon&...
Business Operations and StrategyRegulatory Filings and Compliance
Haleon Updates Share Capital and Voting Rights for Disclosure Purposes
Neutral
Jun 1, 2026
Haleon has confirmed that as of 31 May 2026 it has 8,859,337,794 ordinary shares issued, of which 12,076,964 are held in treasury. This leaves 8,847,260,830 ordinary shares carrying voting rights, a key reference figure for investors and other sta...
Business Operations and StrategyStock Buyback
Haleon advances buyback programme with 10.1 million share cancellation
Positive
Jun 1, 2026
Haleon plc has continued executing its share buyback programme, purchasing 10,149,493 ordinary shares for cancellation across multiple trading venues between 26 and 29 May 2026. Following these transactions, the company’s registered share ca...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon Cancels 2.46 Million Shares in Ongoing Buyback Programme
Positive
May 26, 2026
Haleon PLC has repurchased 2,458,291 of its own ordinary shares for cancellation as part of the share buyback programme launched in March 2026, with purchases executed across the London Stock Exchange, Cboe UK venues and Aquis between 18 and 22 Ma...
DividendsRegulatory Filings and Compliance
Haleon Executives Reinvest Dividends in Additional Shares on London and New York Markets
Positive
May 22, 2026
Haleon PLC disclosed that Chief Financial Officer Dawn Allen and Chief Executive Officer Brian McNamara have acquired additional ordinary shares in the company through dividend reinvestment. Allen purchased 2,596.07411 shares on the London Stock E...
DividendsRegulatory Filings and Compliance
Haleon discloses dividend-driven share purchase by senior independent director
Neutral
May 18, 2026
Haleon plc, the London- and New York-listed consumer health group, concentrates exclusively on everyday health products, investing in research and innovation across categories including oral care, pain relief, respiratory and digestive health. Its...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon Cancels Over 8.3 Million Shares in Ongoing Buyback
Positive
May 18, 2026
Haleon has repurchased 8,316,688 ordinary shares for cancellation under its ongoing buyback programme, with purchases executed between 11 and 15 May 2026 across venues including the London Stock Exchange and Cboe UK. Following these transactions, ...
Stock BuybackRegulatory Filings and Compliance
Haleon Cancels Over 8.3 Million Shares Under Ongoing Buyback Programme
Positive
May 18, 2026
Haleon has repurchased 8,316,688 ordinary shares for cancellation as part of its ongoing share buyback programme launched in March 2026, executing trades between 11 and 15 May across venues including the London Stock Exchange and Cboe UK. Followin...
Stock BuybackFinancial Disclosures
Haleon cancels over 10 million shares in ongoing buyback programme
Positive
May 11, 2026
Haleon has continued executing its previously announced share buyback programme, purchasing 10,205,329 ordinary shares for cancellation across multiple trading venues between 5 and 8 May 2026. Following these transactions, the company’s regi...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Haleon Updates Listing Particulars for £10bn EMTN Programme
Positive
May 7, 2026
Haleon has published updated listing particulars for its £10 billion Euro Medium Term Note programme, issued through Haleon UK Capital plc and Haleon Netherlands Capital B.V. and guaranteed by the parent company. The routine annual update und...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon cancels 12.2 million shares in latest buyback tranche
Positive
May 5, 2026
Haleon plc has executed further purchases of its own ordinary shares as part of the share buyback programme launched in March 2026, acquiring 12,171,987 shares for cancellation across multiple trading venues between 27 April and 1 May. Following t...
Regulatory Filings and Compliance
Haleon Updates Share Capital and Voting Rights for Disclosure Purposes
Neutral
May 1, 2026
Haleon plc has confirmed that, as of 30 April 2026, it has 8,891,932,595 issued ordinary shares, of which 12,240,797 are held in treasury, leaving 8,879,691,798 shares carrying voting rights. This updated share capital and voting rights figure pro...
Business Operations and StrategyExecutive/Board ChangesStock BuybackDividendsShareholder Meetings
Haleon Shareholders Back All Resolutions at 2026 AGM, Endorsing Board and Capital Flexibility
Positive
Apr 29, 2026
Haleon plc reported the voting results of its 2026 annual general meeting, where shareholders approved all resolutions on the agenda by substantial majorities. Ordinary resolutions included receiving the annual report and accounts, approving the d...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Haleon publishes Q1 2026 trading update and schedules investor Q&A
Positive
Apr 29, 2026
Haleon plc said its trading statement for the first quarter of 2026, covering the period to 31 December 2026 year-end, has been published and is now available to investors via the London Stock Exchange’s document service and the company̵...
Business Operations and StrategyStock Buyback
Haleon cancels 8.4 million shares in latest buyback tranche
Positive
Apr 27, 2026
Haleon PLC has repurchased 8,444,107 of its own ordinary shares for cancellation as part of a share buyback programme launched in March 2026, with purchases executed across venues including the London Stock Exchange and Cboe UK between 20 and 24 A...
Business Operations and StrategyStock Buyback
Haleon Cancels 8.7 Million Shares Under Ongoing Buyback Programme
Neutral
Apr 20, 2026
Haleon plc has repurchased 8,740,351 ordinary shares for cancellation as part of its ongoing share buyback programme launched in March 2026, with purchases executed across the London Stock Exchange and multiple alternative UK trading venues betwee...
Stock BuybackRegulatory Filings and Compliance
Haleon Cancels 7.7 Million Shares in Ongoing Buyback Programme
Positive
Apr 13, 2026
Haleon has continued executing its share buyback programme, purchasing 7,740,513 ordinary shares for cancellation between 7 and 10 April 2026 across multiple UK trading venues. Following these transactions, the company’s registered share cap...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon Advances Share Buyback With 5.3 Million Share Cancellation
Positive
Apr 7, 2026
Haleon plc has repurchased 5,266,782 ordinary shares for cancellation under its ongoing share buyback programme, with purchases executed between 30 March and 2 April 2026 across the London Stock Exchange and multiple alternative trading venues. Fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.